bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BIAF bioAffinity Technologies, Inc.

Trading 02-25 15:56:05 EST

1.08

-0.03

-2.70%

High1.10	Low1.04	Vol98.71K
Open1.09	D1 Closing1.11	Amplitude5.40%
Mkt Cap4.86M	Tradable Cap3.67M	Total Shares4.50M
T/O105.24K	T/O Rate2.90%	Tradable Shares3.40M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BIAF","market":"US","secType":"STK","nameCN":"bioAffinity Technologies, Inc.","latestPrice":1.08,"timestamp":1772052901087,"preClose":1.11,"halted":0,"volume":98705,"delay":0,"changeRate":-0.02702702702702705,"floatShares":3401400,"shares":4498700,"eps":-20.279951,"marketStatus":"Trading","change":-0.03,"latestTime":"02-25 15:56:05 EST","open":1.088,"high":1.0999,"low":1.04,"amount":105240.0507695,"amplitude":0.053964,"askPrice":1.08,"askSize":101,"bidPrice":1.06,"bidSize":45,"shortable":3,"etf":0,"ttmEps":-20.279951,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772053200000},"marketStatusCode":2,"adr":0,"listingDate":1662004800000,"exchange":"NASDAQ","adjPreClose":1.11,"preHourTrading":{"tag":"盘前","latestPrice":1.07,"preClose":1.11,"latestTime":"09:28 EST","volume":10026,"amount":11180.3455152,"timestamp":1772029690823,"change":-0.04,"changeRate":-0.036036,"amplitude":0.054054},"postHourTrading":{"tag":"盘后","latestPrice":1.11,"preClose":1.11,"latestTime":"19:48 EST","volume":4687,"amount":5109.2759,"timestamp":1771980482503,"change":0,"changeRate":0,"amplitude":0.043423},"volumeRatio":0.168746},"requestUrl":"/m/hq/s/BIAF/wiki","defaultTab":"wiki","newsList":[{"id":"2614080142","title":"BRIEF-Bioaffinity Announces Validation Study For Lung Cancer Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2614080142","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614080142?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:43","pubTimestamp":1772027014,"startTime":"0","endTime":"0","summary":"BRIEF-Bioaffinity Announces Validation Study For Lung Cancer TestFeb 25 (Reuters) - bioAffinity Technologies Inc BIAF.O:BIOAFFINITY TECHNOLOGIES ANNOUNCES VALIDATION STUDY WITH BROOKE ARMY MEDICAL CEN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA5NNMTD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BIAFW","BK4139"],"gpt_icon":0},{"id":"2614870460","title":"bioAffinity Technologies Partners With Brooke Army Medical Center on CyPath Lung Validation Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2614870460","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614870460?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:31","pubTimestamp":1772026289,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies Inc. has launched a validation study with Brooke Army Medical Center to assess the use of its CyPath Lung test on sputum samples collected via tracheal and bronchial suctioning. The study is expected to enroll about 30 to 50 patients, with results anticipated by mid-2026, and could broaden sample collection options to support earlier lung cancer detection.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire  on February 25, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL67HXS4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"gpt_icon":0},{"id":"2614087033","title":"bioAffinity Technologies Announces Validation Study With Brooke Army Medical Center to Expand SAMPLE Collection Options for the Cypath® Lung Noninvasive Early Detection Lung Cancer Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2614087033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614087033?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:30","pubTimestamp":1772026204,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA5NNMTD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAFW","BK4139","BIAF"],"gpt_icon":0},{"id":"2612289311","title":"bioAffinity Technologies Highlights CyPath Lung Case Study Supporting Noninvasive Lung Cancer Surveillance","url":"https://stock-news.laohu8.com/highlight/detail?id=2612289311","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612289311?lang=en_us&edition=fundamental","pubTime":"2026-02-20 00:00","pubTimestamp":1771516818,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies Inc. announced a new clinical case study describing use of its CyPath Lung noninvasive diagnostic test to help guide management of a 79-year-old patient with a suspicious lung nodule identified on low-dose CT screening. According to the company, the CyPath Lung result was negative and supported a surveillance strategy rather than biopsy; a repeat CT scan later showed resolution of the finding with no pulmonary nodules. The company released the case study with the announcement, indicating the results have already been presented in the published report.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDLbDLHYR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"gpt_icon":0},{"id":"2612988452","title":"bioAffinity Technologies Showcases CyPath Lung Test Clinical Utility in Real-World Case Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2612988452","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612988452?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:02","pubTimestamp":1771333339,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies Inc. announced a new clinical case study demonstrating the clinical utility of its CyPath Lung test, a noninvasive diagnostic tool for lung cancer. The case involved a high-risk patient with multiple pulmonary nodules, where the CyPath Lung test supported evidence-based surveillance decisions and guideline-consistent follow-up intervals. The results of the case study have been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire  on February 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL2mNRzk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2610556516","title":"BioAffinity Technologies announces new appointments to Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2610556516","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610556516?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:37","pubTimestamp":1770644241,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies (BIAF) announced new appointments to its Medical and Scientific Advisory Board, including: David Ost; Daniel Sterman; and ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-announces-new-appointments-to-advisory-board-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-announces-new-appointments-to-advisory-board-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2610283658","title":"bioAffinity Technologies Expands Advisory Board With Leading Lung Cancer Experts","url":"https://stock-news.laohu8.com/highlight/detail?id=2610283658","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610283658?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:01","pubTimestamp":1770642069,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies Inc. has expanded its Medical and Scientific Advisory Board with the addition of David Ost, MD, MPH, Daniel Sterman, MD, and J. Scott Ferguson, MD. The new members join as the company focuses on advancing adoption of its CyPath Lung diagnostic test for early lung cancer detection.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire  on February 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL11Mk0v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"gpt_icon":0},{"id":"2601803920","title":"bioAffinity Technologies’ Precision Pathology Laboratory Services Maintains CAP Accreditation","url":"https://stock-news.laohu8.com/highlight/detail?id=2601803920","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601803920?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:01","pubTimestamp":1767790869,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire  on January 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL2gtzZp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2593083453","title":"bioAffinity Technologies' Precision Pathology Laboratory Services Finalizes Succession with Dr. Humphreys as New Owner","url":"https://stock-news.laohu8.com/highlight/detail?id=2593083453","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593083453?lang=en_us&edition=fundamental","pubTime":"2025-12-23 06:10","pubTimestamp":1766441400,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies Subsidiary Precision Pathology Laboratory Services Finalizes Succession Agreement with Dr. Humphreys. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 22, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL3pq8cx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"gpt_icon":0},{"id":"2588467270","title":"bioAffinity Technologies Showcases CyPath Lung Test Success in Early Lung Cancer Detection at NLCRT","url":"https://stock-news.laohu8.com/highlight/detail?id=2588467270","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588467270?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:01","pubTimestamp":1764766871,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies Inc. announced that its Chief Medical Officer, Dr. Gordon Downie, will present a poster at the American Cancer Society National Lung Cancer Roundtable annual meeting on December 8, 2025. The poster highlights three clinical cases in which the company's noninvasive CyPath Lung test, a sputum-based flow cytometry diagnostic, successfully identified Stage 1A lung cancer in patients with diagnostically challenging presentations. The results demonstrate the use of CyPath Lung alongside standard diagnostic tools, providing actionable results that led to early-stage confirmed diagnoses. The poster session will be held from 2:35-3:15 p.m. ET and will also be available on the bioAffinity website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL92TbXp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2583506133","title":"bioAffinity Technologies Reports Q3 Revenue of $1.5 Million and Net Loss of $5.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506133","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583506133?lang=en_us&edition=fundamental","pubTime":"2025-11-14 21:01","pubTimestamp":1763125271,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies Inc. reported total revenue of $1.5 million for the third quarter ended September 30, 2025, down from $2.4 million in the same period of 2024, primarily due to the discontinuation of unprofitable pathology services. CyPath Lung testing revenue for the quarter increased approximately 122% year-over-year, reflecting higher physician adoption and test volume. Net loss for the quarter was $5.1 million, or $4.74 per share, compared to a net loss of $2.0 million, or $4.84 per share, in the third quarter of 2024, mainly due to the change in fair value of warrants issued. Operating expenses fell 16% year-over-year to $3.7 million, while depreciation and amortization expense declined 25% to $113,000. Cash and cash equivalents rose to $7.7 million as of September 30, 2025, following $10.4 million in gross proceeds from equity transactions. Sales of CyPath Lung reached a record high in the third quarter, increasing 92% over the previous quarter, with notable growth in ado","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL71t9cp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2581727252","title":"bioAffinity Technologies Reports 111% Increase in CyPath Lung Test Volume in October","url":"https://stock-news.laohu8.com/highlight/detail?id=2581727252","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581727252?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:00","pubTimestamp":1762347654,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies Inc. reported continued growth in the sales of its CyPath Lung diagnostic test for lung cancer. In October 2025, the number of CyPath Lung tests processed increased by 111% over the 2025 year-to-date monthly average. The company also noted that third-quarter sales volume rose 95% compared to the prior quarter. Additionally, medical practices with multiple CyPath Lung orders increased by 106% in the third quarter over the previous quarter, and by 67% in October compared to the 2025 year-to-date monthly average. The company stated that these results reflect steady month-over-month and quarter-over-quarter growth throughout the first ten months of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Te","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL6nVzmz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"gpt_icon":0},{"id":"2578959591","title":"bioAffinity Technologies Announces Acceptance of Australian Patent Application for Lung Disease Diagnostic Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2578959591","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578959591?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:04","pubTimestamp":1761653051,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies announced that the Australian Patent Office has accepted its patent application for a proprietary platform designed to detect and characterize multiple lung diseases. The patent application, titled \"System and Method for Determining Lung Health,\" covers technology that uses flow cytometry and fluorescent probes to identify disease-related cellular and molecular changes in sputum samples. The accepted Australian patent application complements the company's existing intellectual property portfolio, which includes awarded and pending patents in several international jurisdictions. The patent will be automatically issued three months after acceptance unless formally opposed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL6HW0ky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"gpt_icon":0},{"id":"2576505859","title":"bioAffinity Technologies Unveils New Research Supporting CyPath Lung Test at CHEST 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2576505859","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576505859?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:00","pubTimestamp":1760961655,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies Inc. has announced that it will present new research supporting the methods used for collecting and transporting patient samples for its noninvasive CyPath Lung test at CHEST 2025, the annual meeting of the American College of Chest Physicians. The study, titled \"The Effect of Sputum Storage and Shipping Temperature on Flow Cytometric Outcomes of Sputum-Based Diagnostic Tests,\" will be presented by Dr. Rossella Titone on October 22, 2025. The research highlights protocols for handling clinical samples collected at home and returned to the laboratory, with physicians typically receiving results within two days. The company has previously reported that CyPath Lung has detected lung cancer at early, potentially curative stages.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL30Cb5k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2576086316","title":"Why Did bioAffinity Technologies' Stock Slip In After-Hours Trading After A Big Day Of Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2576086316","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576086316?lang=en_us&edition=fundamental","pubTime":"2025-10-17 14:53","pubTimestamp":1760683980,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies' stock surged after a patent notice and Nasdaq compliance update but slipped in after-hours trading.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/17/Rising-stock-market.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/17/Rising-stock-market.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/10/48268789/why-did-bioaffinity-technologies-stock-slip-in-after-hours-trading-after-a-big-day-of-gains","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/10/48268789/why-did-bioaffinity-technologies-stock-slip-in-after-hours-trading-after-a-big-day-of-gains","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2575274552","title":"bioAffinity Technologies Receives USPTO Allowance for Patent Covering AI-Based Lung Cancer Diagnostic Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2575274552","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575274552?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:01","pubTimestamp":1760616096,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies announced it has received a notification of allowance from the United States Patent and Trademark Office for a new patent covering its AI-built algorithm and flow cytometry platform used in the detection of early-stage lung cancer. The patent, titled \"Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning,\" protects a system and method for predicting the likelihood of lung cancer by analyzing sputum samples. The technology leverages artificial intelligence to analyze immune cells, apoptotic cells, and cancer-related cells, combined with patient age, to deliver high-precision, data-driven diagnostic results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Te","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL26Dtkk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2575354745","title":"bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2575354745","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575354745?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:00","pubTimestamp":1760616003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUAJNK37:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIAF","BIAFW"],"gpt_icon":0},{"id":"2575278144","title":"bioAffinity Technologies Regains Nasdaq Compliance, Avoids Delisting After Meeting Listing Standards","url":"https://stock-news.laohu8.com/highlight/detail?id=2575278144","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575278144?lang=en_us&edition=fundamental","pubTime":"2025-10-15 20:00","pubTimestamp":1760529646,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies Inc. announced that it has regained compliance with all applicable Nasdaq continued listing requirements. The company received written notice from Nasdaq confirming that its common stock and warrants will continue to trade on the Nasdaq Capital Market under the symbols BIAF and BIAFW. This follows the company's compliance with Nasdaq Listing Rule 5550, which requires a minimum closing bid price of $1.00 per share, and Nasdaq Listing Rule 5550, which mandates a minimum of $2.5 million in stockholders' equity. The company will be subject to a one-year Mandatory Panel Monitor period, during which any failure to comply with the equity rule could lead to delisting, although a hearing may be requested before any final action.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDLc5BK0V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"gpt_icon":0},{"id":"2575781172","title":"bioAffinity Technologies Regains Compliance With Nasdaq Listing Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2575781172","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575781172?lang=en_us&edition=fundamental","pubTime":"2025-10-15 20:00","pubTimestamp":1760529605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nTUA3GYFPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIAF","BIAFW"],"gpt_icon":0},{"id":"2574402198","title":"Wallachbeth Capital Announces the Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2574402198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574402198?lang=en_us&edition=fundamental","pubTime":"2025-10-10 02:01","pubTimestamp":1760032861,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nTUA8H3MD4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAF","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bioaffinitytech.com;ir.bioaffinitytech.com","stockEarnings":[{"period":"1week","weight":0.0374},{"period":"1month","weight":-0.1778},{"period":"3month","weight":-0.2345},{"period":"6month","weight":-0.8487},{"period":"1year","weight":-0.9526},{"period":"ytd","weight":-0.0593}],"compareEarnings":[{"period":"1week","weight":0.0066},{"period":"1month","weight":-0.0027},{"period":"3month","weight":0.0113},{"period":"6month","weight":0.0592},{"period":"1year","weight":0.1509},{"period":"ytd","weight":0.008}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.125018},{"month":2,"riseRate":0.25,"avgChangeRate":-0.059822},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.165848},{"month":4,"riseRate":1,"avgChangeRate":0.35077},{"month":5,"riseRate":0,"avgChangeRate":-0.162067},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.024762},{"month":7,"riseRate":0.666667,"avgChangeRate":0.072762},{"month":8,"riseRate":0,"avgChangeRate":-0.216971},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.17769},{"month":10,"riseRate":0.25,"avgChangeRate":-0.105345},{"month":11,"riseRate":0.25,"avgChangeRate":-0.068737},{"month":12,"riseRate":0,"avgChangeRate":-0.246482}],"exchange":"NASDAQ","name":"bioAffinity Technologies, Inc.","nameEN":"bioAffinity Technologies, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest bioAffinity Technologies, Inc.(BIAF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"bioAffinity Technologies, Inc.,BIAF,bioAffinity Technologies, Inc.股票,bioAffinity Technologies, Inc.股票老虎,bioAffinity Technologies, Inc.股票老虎国际,bioAffinity Technologies, Inc.行情,bioAffinity Technologies, Inc.股票行情,bioAffinity Technologies, Inc.股价,bioAffinity Technologies, Inc.股市,bioAffinity Technologies, Inc.股票价格,bioAffinity Technologies, Inc.股票交易,bioAffinity Technologies, Inc.股票购买,bioAffinity Technologies, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest bioAffinity Technologies, Inc.(BIAF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}